<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03100591</url>
  </required_header>
  <id_info>
    <org_study_id>AC-080-104</org_study_id>
    <nct_id>NCT03100591</nct_id>
  </id_info>
  <brief_title>A Study to Evaluate ACT-132577 in Healthy Male Subjects</brief_title>
  <official_title>Single-center, Open-label Study With 14C-radiolabeled ACT-132577 to Investigate the Mass Balance, Pharmacokinetics, and Metabolism Following Single Oral Administration to Healthy Male Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Actelion</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Actelion</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary purpose of this study is to investigate the rate and routes (urine and feces) of
      elimination of ACT-132577, and the mass balance in urine and feces
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">March 28, 2017</start_date>
  <completion_date type="Actual">April 18, 2017</completion_date>
  <primary_completion_date type="Actual">April 18, 2017</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Cumulative excretion of radioactivity in urine and feces</measure>
    <time_frame>From study treatment administration up to day 15</time_frame>
    <description>14C-radioactivity will be measured daily in urine and feces samples for determination of total radioactivity recovery</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of subjects with treatment-emergent adverse events and serious adverse events</measure>
    <time_frame>From study treatment administration up to day 32</time_frame>
    <description>Collection of any adverse event at each dose level</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum plasma concentration (Cmax) of 14C-radiolabeled ACT-132577</measure>
    <time_frame>From study treatment administration up to day 15</time_frame>
    <description>Cmax is directly derived from the observed plasma concentrations of ACT-132577 and its metabolites</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to reach Cmax (tmax) of 14C-radiolabeled ACT-132577</measure>
    <time_frame>From study treatment administration up to day 15</time_frame>
    <description>tmax is directly derived from the observed plasma concentrations of ACT-132577 and its metabolites</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Terminal half-life (t1/2) of 14C-radiolabeled ACT-132577</measure>
    <time_frame>From study treatment administration up to day 15</time_frame>
    <description>t1/2 is calculated from the terminal rate constant obtained from the plasma concentrations-time curves of ACT-132577 and its metabolites</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the plasma concentration-time curve (AUC) of 14C-radiolabeled ACT-132577</measure>
    <time_frame>From study treatment administration up to day 15</time_frame>
    <description>AUC is defined for the time intervals from zero to time t of the last measured concentration above the limit of quantification and from zero to infinity</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum plasma concentration (Cmax) of ACT-132577 and its metabolites</measure>
    <time_frame>From study treatment administration up to day 15</time_frame>
    <description>Cmax is directly derived from the observed plasma concentrations of ACT-132577 and its metabolites</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to reach Cmax (tmax) of ACT-132577 and its metabolites</measure>
    <time_frame>From study treatment administration up to day 15</time_frame>
    <description>tmax is directly derived from the observed plasma concentrations of ACT-132577 and its metabolites</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Terminal half-life (t1/2) of ACT-132577 and its metabolites</measure>
    <time_frame>From study treatment administration up to day 15</time_frame>
    <description>t1/2 is calculated from the terminal rate constant obtained from the plasma concentrations-time curves of ACT-132577 and its metabolites</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the plasma concentration-time curve (AUC) ACT-132577 and its metabolites</measure>
    <time_frame>From study treatment administration up to day 15</time_frame>
    <description>AUC is defined for the time intervals from zero to time t of the last measured concentration above the limit of quantification and from zero to infinity</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">6</enrollment>
  <condition>Healthy Subjects</condition>
  <arm_group>
    <arm_group_label>14C-radiolabelled ACT-132577</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>On Day 1, subjects will receive a single oral dose of 25 mg 14C-radiolabeled ACT-132577, administered as an oral formulation in the fasted state</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>14C-radiolabeled ACT-132577</intervention_name>
    <description>Single oral dose of 3.7 megabecquerel (MBq) (100 microcurie [μCi]) 14C-radiolabeled ACT-132577 administered as 1 capsule of 25 mg</description>
    <arm_group_label>14C-radiolabelled ACT-132577</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Signed informed consent in a language understandable to the subject prior to any
             study-mandated procedure;

          -  Healthy male subjects aged between 45 and 65 years (inclusive) at screening;

          -  Body mass index of 18.0 to 28.0 kg/m2 (inclusive) at screening;

          -  Healthy on the basis of physical examination, cardiovascular assessments and
             laboratory tests.

        Exclusion Criteria:

          -  Values of hepatic aminotransferase (alanine aminotransferase and/or aspartate
             aminotransferase) &gt; 3 × upper limit of normal range at screening;

          -  Hemoglobin &lt; 100 g/L at screening;

          -  Known hypersensitivity to ACT-132577 or drugs of the same class, or any excipient of
             the ACT-132577 drug formulation;

          -  Known hypersensitivity or allergy to natural rubber latex;

          -  Previous exposure to ACT-132577;

          -  Treatment with another investigational drug within 3 months prior to screening or
             participation in more than 4 investigational drug studies within 1 year prior to
             screening;

          -  Any circumstances or conditions, which, in the opinion of the investigator, may affect
             full participation in the study or compliance with the protocol;

          -  A radiation burden of &gt; 0.1 milliSievert (mSv) and ≤ 1.0 mSv in the period of 1 year
             prior to screening; a radiation burden of ≥ 1.1 mSv and ≤ 2.0 mSv in the period of 2
             years prior to screening, etc. (add 1 year per 1 mSv).
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>45 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>JP Jones, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Actelion</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>PRA Health Sciences</name>
      <address>
        <city>Groningen</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>July 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 29, 2017</study_first_submitted>
  <study_first_submitted_qc>March 29, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">April 4, 2017</study_first_posted>
  <last_update_submitted>July 26, 2017</last_update_submitted>
  <last_update_submitted_qc>July 26, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">July 27, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

